𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting

✍ Scribed by J. B. Whitmore; Mark G. Kris; Paul J. Hesketh; Thomas H. Grote; Dawn M. DuBois; Michael B. Cramer; William F. Hahne

Publisher
Springer-Verlag
Year
1998
Tongue
English
Weight
71 KB
Volume
6
Category
Article
ISSN
0941-4355

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High versus low dose granisetron, a sele
High versus low dose granisetron, a selective 5HT3antagonist, for the prevention of chemotherapy-induced nausea and vomiting
✍ H. C. Falkson; C. I. Falkson; G. Falkson 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 173 KB

Fifty six patients, with histologically confirmed cancer, who received highly emetogenic chemotherapy, were entered on a randomized double blind, low versus high dose, study of granisetron, a 5HT3 receptor antagonist. A single dose of intravenous granisetron protected the majority of patients from n

Establishing the dose of the oral NK1 an
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting
✍ Sant P. Chawla; Steven M. Grunberg; Richard J. Gralla; Paul J. Hesketh; Cindy Ri 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB

## Abstract ## BACKGROUND The neurokinin‐1 antagonist aprepitant (EMEND™; Merck Research Laboratories, West Point, PA) has been shown to reduce chemotherapy‐induced nausea and vomiting when it is given with a 5‐hydroxytryptamine‐3 receptor antagonist and dexamethasone. The current study sought to

Randomized, placebo-controlled, pilot st
Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting
✍ Jon D. Herrington; Adam D. Jaskiewicz; Juhee Song 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB

## Abstract ## BACKGROUND. The combination of palonosetron and aprepitant is safe and effective in the prevention of chemotherapy‐induced emesis (CIE). The purpose of this pilot study was to ascertain the effectiveness of 1‐day versus 3‐day aprepitant in the prevention of acute and delayed nausea